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Abstract
Immunogenicity is considered one important criterion for progres-
sion of candidate vaccines to further clinical evaluation. We tested
this assumption in an infection and vaccination model for malaria
pre-erythrocytic stages. We engineered Plasmodium berghei parasites
that harbour a well-characterised epitope for stimulation of CD8+ T
cells, either as an antigen in the sporozoite surface-expressed
circumsporozoite protein or the parasitophorous vacuole membrane
associated protein upregulated in sporozoites 4 (UIS4) expressed in
exo-erythrocytic forms (EEFs). We show that the antigen origin
results in profound differences in immunogenicity with a sporozoite
antigen eliciting robust, superior antigen-specific CD8+ T-cell
responses, whilst an EEF antigen evokes poor responses. Despite
their contrasting immunogenic properties, both sporozoite and EEF
antigens gain access to antigen presentation pathways in hepato-
cytes, as recognition and targeting by vaccine-induced effector CD8+
T cells results in high levels of protection when targeting either anti-
gen. Our study is the first demonstration that poorly immunogenic
EEF antigens do not preclude their susceptibility to antigen-specific
CD8+ T-cell killing, which has wide-ranging implications on antigen
prioritisation for next-generation pre-erythrocytic malaria vaccines.
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Introduction
Malaria caused by the apicomplexan parasite Plasmodium is respon-
sible for more than 229 million clinical cases and over 409,000
deaths annually worldwide, with more than 97% of cases attribu-
table to Plasmodium falciparum (WHO, 2020). Whilst current
malaria control strategies have led to marked reduction in incidence
rate, cases and mortality for the past 16 years, a highly efficacious
vaccine is likely essential to approach the ambitious World Health
Organisation’s (WHO) vision of “a world free of malaria”. Targeting
the malaria pre-erythrocytic stages, an obligatory and clinically
silent phase of the parasite’s life cycle, is considered an ideal and
attractive strategy for vaccination; inhibiting parasite infection of,
and development in hepatocytes results in preclusion of both
disease-causing blood stages and transmissible sexual stages. Yet,
despite intensive research for over 35 years, a highly efficacious
pre-erythrocytic stage vaccine remains elusive (Draper et al, 2018).
An in-depth characterisation of how the complex biology of pre-
erythrocytic stages influences the generation and protective efficacy
of immune responses is warranted to inform the design of future
malaria vaccines.
CD8+ T cells are crucial mediators of protective immunity to
malaria pre-erythrocytic stages (Doolan & Hoffman, 2000). Whilst
often considered as a single phase of the parasite’s life cycle, the
malaria pre-erythrocytic stage is comprised of two different parasite
forms: (i) sporozoites, which are motile extracellular parasites that
are delivered by infected mosquitoes to the mammalian host, and (ii)
exo-erythrocytic forms (EEF; also known as liver stages), which are
intracellular parasites resulting from the differentiation and growth
of sporozoites inside a parasitophorous vacuole (PV) within hepato-
cytes (Hafalla et al, 2011). How these two spatially different parasite
forms and the ensuing temporal expression of parasite-derived anti-
gens impact the magnitudes, kinetics and phenotypes of CD8+ T-cell
responses elicited following infection is poorly understood. Further-
more, the complexity within the pre-erythrocytic stages has fuelled a
long-standing debate focussed on the contributions of distinct sporo-
zoite and EEF antigens in parasite-induced responses, and whether
sporozoite or EEF proteins are better targets of vaccines.
Our current understanding of CD8+ T-cell responses to malaria
pre-erythrocytic stages has been largely based on measuring
1 Parasitology Unit, Max Planck Institute for Infection Biology, Berlin, Germany
2 Department of Molecular Parasitology, Institute of Biology, Humboldt University, Berlin, Germany
3 Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
4 Jenner Institute, University of Oxford, Oxford, UK
5 Sorbonne Universite, INSERM, CNRS, Centre d’Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France
*Corresponding author. Tel: +44 020 7958 8129; E-mail: julius.hafalla@lshtm.ac.uk
†These authors contributed equally to this work
‡Present address: Wellcome Centre for Integrative Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
#Present address: Instituto Politecnico Nacional, IPN. Av. Luis Enrique Erro s/n, Unidad Adolfo Lopez Mateos, Mexico City, Mexico
ª 2021 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 13: e13390 | 2021 1 of 15
responses to the H-2-Kd-restricted epitopes of rodent P. yoelii (Py)
(Weiss et al, 1990) and P. berghei (Pb) (Romero et al, 1989) circum-
sporozoite proteins (CSP), the major surface antigen of sporozoites.
Many of these fundamental studies have focussed on using infec-
tions with irradiated sporozoites, the benchmark vaccine model for
malaria. Infection with Py sporozoites elicits an expected T-cell
response typified by early activation and induction of effector CSP-
specific CD8+ T cells followed by contraction and establishment of
quantifiable memory populations (Sano et al, 2001). CSP-specific
CD8+ T cells are primed by dendritic cells that cross-present sporo-
zoite antigens via the endosome-to-cytosol pathway (Cockburn
et al, 2011). Yet, CSP is a unique antigen because it is expressed in
both sporozoites and EEFs (Hollingdale et al, 1983). Whilst the
expression of CSP mRNA ceases after sporozoite invasion, the
protein on the parasite surface is stable and endures in EEFs during
development in hepatocytes (Silvie et al, 2014). In vitro data indi-
cate that primary hepatocytes process and present PbCSP-derived
peptides to CD8+ T cells in a proteasome-dependent manner, involv-
ing export of antigen to the cytosol (Cockburn et al, 2011). Taken
together, these data imply that sporozoite antigens induce quan-
tifiable CD8+ T-cell responses after infection. Antigens that have
similar expression to the CSP, persisting to EEFs and with epitope
determinants presented on hepatocytes, are excellent targets of
CD8+ T cell-based vaccines.
The paucity of EEF only-specific epitopes has hindered not only
our ability to understand the immune responses that are evoked
whilst the parasite is in the liver, but also their utility as targets of
vaccination. Accordingly, the contribution of EEF-infected hepato-
cytes in the in vivo induction of CD8+ T-cell responses is poorly
understood. The liver is an organ where the primary activation of
CD8+ T cells is generally biased towards the induction of tolerance
(Thomson & Knolle, 2010; Bertolino & Bowen, 2015). Yet, studies in
other model systems have demonstrated antigen-specific primary
activation within the liver (Bertolino et al, 2001). Another confound-
ing issue with EEFs is their development in PVs with constrained
access to the hepatocyte’s cytosol (Hafalla et al, 2011). Nonetheless,
if CD8+ T cells specific for EEF antigens are primed, do they expand
and contract with distinct kinetics? Moreover, are EEF-specific
epitopes efficiently generated for recognition and targeting by
vaccine-induced CD8+ T cells? Answers to these questions will be
key for antigen selection and design of future malaria vaccines.
In this study, we compared the initiation and development of
CD8+ T-cell responses—elicited following parasite infection—to
CSP, a sporozoite antigen, and to upregulated in infective sporo-
zoites gene 4 (UIS4), an EEF-specific vacuolar protein (Mueller et al,
2005). UIS4, a member of the early transcribed membrane protein
(ETRAMP) family, is abundantly expressed in EEFs and associates
with the PVM (Mueller et al, 2005). Whilst UIS4 mRNA expression
is present in sporozoites, translation is repressed until when EEFs
develop (Silvie et al, 2014). To control for epitope specificity, we
generated Pb transgenic parasites that incorporate the MHC class I
H-2-Kb epitope SIINFEKL, from ovalbumin, in either the CSP or UIS4
protein. The resulting transgenic parasites develop normally as
wild-type (WT) Pb in the mosquito vector and mammalian host.
However, SIINFEKL would be expressed at the same time and space
as its respective Plasmodium protein, enabling the CD8+ T-cell
response against these proteins to be tracked in an epitope-specific
physiological manner. In line with previous studies (Cockburn et al,
2011; Montagna et al, 2014), to augment low numbers of CD8+ T
cells in the na€ıve response, cells from OT-I mice, which express
SIINFEKL-specific T-cell receptors (TCRs) on their CD8+ T cells,
were initially adoptively transferred to mice prior to them receiving
sporozoite immunisations. Furthermore, we evaluated the capacity
of vaccine-induced CD8+ T cells to target these parasites in a mouse
challenge model. Our data show disparate immunogenic properties
between a sporozoite and an EEF vacuolar membrane antigen but
equivalent susceptibility to vaccine-induced CD8+ T cells.
Results
Transgenic CSPSIINFKEL and UIS4SIINFEKL parasites display normal
sporozoite motility and liver invasion
We generated, by double homologous recombination, transgenic Pb
parasites expressing the immunodominant H-2-Kb-restricted CD8+ T-
cell epitope of ovalbumin (SIINFEKL) in the context of the sporo-
zoite surface antigen CSP or the EEF vacuolar membrane antigen
UIS4 (Figs 1A and EV1A and B). Constructs included the TgDHFR/
TS-positive selection cassette and incorporated SIINFEKL in the
context of the gene open reading frame. For CSPSIINFEKL, SIINFEKL
replaced SYIPSAEKI, the immunodominant H-2-Kd-restricted CD8+
T-cell epitope of CSP, which allowed for recognition in H-2-Kb-carry-
ing C57BL/6 mice. For UIS4SIINFEKL, the SIINFEKL epitope was
added to the immediate C terminus of the UIS4 protein. Appending
the C terminus was chosen because it had been shown in Toxo-
plasma gondii that the potency of the immunodominant epitope of
GRA6 was associated with its C-terminal location, which may have
enhanced the presentation by parasite-infected cells (Feliu et al,
2013). Whilst undefined for UIS4 itself, it has been shown for
several other ETRAMPs that the C terminus faces the host cell cyto-
plasm (Spielmann et al, 2003), which is likely to facilitate exposure
to the MHC I complex.
The resulting parasites showed a phenotype comparable to WT
parasites, with comparable mosquito infectivity and number of sali-
vary gland sporozoites (Fig EV1C and D), functional sporozoite
motility (Fig 1B) and normal invasive capacity and development
inside hepatocytes (Figs 1C and EV1E). Thus, the introduced muta-
tions to generate CSPSIINFEKL and UIS4SIINFEKL parasites did not inter-
fere with the completion of the life cycle, in either mosquito vector
or mouse. All C57BL/6 mice that received 800 sporozoites of either
CSPSIINFKEL or UIS4SIINFEKL intravenously developed a detectable
(patent) blood stage infection by day 4, comparable to infection with
WT sporozoites (Fig EV1F).
Peripheral blood CD8+ T-cell responses are superior if elicited by
a sporozoite surface protein in contrast to a vacuolar membrane
protein in the infected liver
We first wanted to determine whether the generated transgenic
parasites allow antigen-specific responses to be tracked using SIIN-
FEKL as a surrogate CD8+ T-cell epitope for sporozoite surface and
EEF vacuolar membrane antigens. To this end, we assessed the
kinetics of the CD8+ T-cell response following intravenous immuni-
sation with CSPSIINFEKL or UIS4SIINFEKL sporozoites. To augment the
CD8+ T-cell response, mice were adoptively transferred with 2 × 106
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OT-I cells expressing a SIINFEKL-specific TCR (Cockburn et al,
2011), prior to receiving 10,000 c-radiation attenuated WT, CSPSIINFEKL
or UIS4SIINFEKL sporozoites. Prior work showed that c-radiation
attenuation of P. berghei sporozoites does not impact host cell inva-
sion and UIS4 expression (Mac-Daniel et al, 2014).
Peripheral blood was taken at days 4, 7, 14, 21, 42 and 88 after
immunisation and CD8+ T-cell responses were analysed after stain-
ing with H-2-Kb-SIINFEKL pentamers and for CD11a, a marker for
antigen-experienced T cells (Rai et al, 2009; Schmidt et al, 2010)
(Fig 2A and B). Additional gating strategies for the characterisation
of Kb-SIINFEKL+ CD8+ T cells are shown in Appendix Fig S1. A
substantial proportion of Kb-SIINFEKL+ CD11ahi CD8+ T cells were
observed in mice immunised with CSPSIINFEKL; the response was
highest on day 4, reaching 5% of all antigen-experienced CD8+
T cells, and declined steadily until day 21, when the response stabi-
lised and remained unchanged for several weeks (Fig 2C). In
marked contrast, UIS4SIINFEKL immunisation induced a poor CD8+ T-
cell response; the proportion of Kb-SIINFEKL+ CD11ahi CD8+ T cells
was only higher than the control groups at day 4 after immunisa-
tion, and the response remained within background levels for the
duration of the experiment. Control groups included mice receiving
OT-I cells only or in addition to c-radiation attenuated WT sporo-
zoites, which lack SIINFEKL sequences.
The poor CD8+ T-cell response induced by UIS4SIINFEKL sporo-
zoites, as compared to CSPSIINFEKL, led us to characterise the early
events in the proliferation and differentiation of these cells. Mice
were adoptively transferred with CFSE-labelled OT-I cells and
immunised with c-radiation attenuated WT, CSPSIINFEKL or
UIS4SIINFEKL sporozoites. As shown by gating on CD8+ T cells
(Fig 2D and E), after 5 days, immunisation with CSPSIINFEKL
sporozoites led to greater expansion of Kb-SIINFEKL+ CD8+ T cells,
as compared to that observed with UIS4SIINFEKL sporozoites
(Fig EV2A), in good agreement with the peripheral blood data
described above (Fig 2C). Consistent with the activation of these
cells, the proliferation of antigen-specific CD8+ T cells by both para-
sites was associated with the development of effector and effector
memory phenotypes as evidenced by upregulation of CD11a
and CD49d, and downregulation of CD62L, respectively (Figs 2F–H
and EV2B–D).
Taken together, these findings establish that immunisations with
c-radiation attenuated CSPSIINFEKL and UIS4SIINFEKL sporozoites
permit antigen-specific responses to be tracked longitudinally in the
peripheral blood. Importantly, we demonstrate that a sporozoite
surface protein evokes a CD8+ T-cell response of superior magnitude
than an EEF vacuolar membrane protein following immunisation
with malaria sporozoites.
Higher magnitude of splenic and intrahepatic CD8+ T-cell
responses to a sporozoite antigen
Previous research has shown that CD8+ T cells are primed
primarily in the spleen following intravenous immunisation with
malaria sporozoites (Lau et al, 2014) and that liver lymphocytes
form a front-line defence against developing EEFs in hepatocytes
(Guebre-Xabier et al, 1999; Fernandez-Ruiz et al, 2016). Thus, we
further analysed the development of CD8+ T-cell responses in the
spleens and livers of mice adoptively transferred with OT-I cells
and intravenously immunised with c-radiation attenuated WT,
CSPSIINFEKL or UIS4SIINFEKL sporozoites. Consistent with our afore-
mentioned results, surface staining of splenic and liver lympho-
cytes showed higher proportion and absolute numbers of Kb-
SIINFEKL+ CD11ahi CD8+ T cells at day 14 and day 42 following
immunisation with CSPSIINFEKL compared with UIS4SIINFEKL sporo-
zoites (Fig 3A–D). In addition, the proportions of CD11ahi,
CD62Llo, CD49dhi and CD44hi expressing splenic and liver CD8+ T
cells, elicited by both CSPSIINFEKL and UIS4SIINFEKL sporozoites,
were comparable, indicative of effector and effector memory cell
phenotypes (Fig EV3). Although low, the numbers of antigen-
specific CD8+ T cells induced by UIS4SIINFEKL sporozoites were
within the detection limits of the assay.
To assess for effector functions, splenic and liver lymphocytes
were stimulated ex vivo with the SIINFEKL peptide. Generally,
A
B C
Figure 1. Generation and characterisation of recombinant CSPSIINFEKL
and UIS4SIINFEKL P. berghei parasites.
Plasmodium berghei parasites expressing the CD8+ T-cell epitope of ovalbumin,
SIINFEKL, in the context of CSP or UIS4 were generated using double
homologous recombination.
A Schematic overview of transgenic parasite lines. To generate CSPSIINFEKL,
SIINFEKL replaced amino acids SYIPSAEK in CSP. To generate UIS4SIINFEKL,
SIINFEKL was adjoined to the carboxyl-terminus of the UIS4 protein.
B Sporozoite immunofluorescent antibody staining of WT, CSPSIINFEKL or
UIS4SIINFEKL sporozoites after gliding on BSA-coated glass slides. Shown are
microscopic images of the respective sporozoites that were stained with
anti-CSP (green), anti-UIS4 (red) and nuclear stain Hoechst (blue). Scale
bars, 10 lm. The numbers show mean percentage ( SD) of sporozoites
with trails assessed from ≥ 220 sporozoites.
C Fluorescent-microscopic images of EEF-infected Huh7 hepatoma cells. 24
and 48 h after infection with WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites, the
cells were fixed and stained with anti-UIS4 (red), anti-HSP70 (green) and
the nuclear stain Hoechst (blue). Scale bars, 10 µm. The numbers show
mean numbers ( SD) of intracellular parasites counted per well of 8-well
Labtek slides.
Data information: The data shown are representative from one of two
independent experiments.
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higher numbers (proportion and absolute numbers) of IFN-c-secret-
ing CD8+ T cells were observed at day 14 and day 42 following
immunisation with CSPSIINFEKL compared with UIS4SIINFEKL sporo-
zoites (Fig 3E–G). In addition, these CD8+ T cells also expressed
TNF and IL-2 in a similar differential pattern, suggesting potential
polyfunctionality (Fig EV4). Additional gating strategies for the
characterisation of IFN-c-secreting CD8+ T cells are shown in
Appendix Fig S2.
Altogether, even though effector and effector memory CD8+ T-
cell responses can be detected against both sporozoite surface
protein and EEF vacuolar membrane protein antigens following
immunisation with c-radiation attenuated sporozoites, the two
antigens show a striking difference in the magnitude of CD8+ T-cell
responses they induce.
Higher magnitude of endogenously produced splenic and
intrahepatic antigen-specific CD8+ T-cell responses to a
sporozoite antigen
Previous work tracking responses to SIINFEKL-tagged proteins has
used adoptively transferred cells from OT-I mice, with all T cells
from these mice expressing T-cell receptors specific to SIINFEKL
(Cockburn et al, 2011; Montagna et al, 2014). We employed this








Figure 2. Sporozoite antigen exposure elicits superior peripheral blood CD8+ T-cell responses.
A Schematic overview of experimental design. C57BL/6 mice received 2 × 106 OT-I cells alone or were additionally immunised with 10,000 c-radiation attenuated
parasites intravenously.
B Flow cytometry plots show the gating strategy for identifying Kb-SIINFEKL+ CD11ahi CD8+ T cells.
C Temporal analysis of antigen-specific CD8+ T-cell responses. Peripheral blood was obtained on days 4, 7, 14, 21, 42 and 88 post-immunisation with WT (triangles;
n = 3–9), CSPSIINFEKL (orange squares; n = 4–8) or UIS4SIINFEKL (blue circles; n = 4–10) sporozoites, or no parasites (diamonds; n = 2–5) and stained for Kb-SIINFEKL+
CD11ahi CD8+ T cells. Line graph shows mean values ( SEM) from representative experiments. (*P < 0.05; **P < 0.01; ***P < 0.001; Welch’s t-test comparing
CSPSIINFEKL and UIS4SIINFEKL). See Appendix Table S1 for the number of mice used per timepoint and per group. See Appendix Table S4 for exact P-values.
D–H C57BL/6 mice (n = 4 per group), which received 2 × 106 CFSE-labelled OT-I splenocytes, were immunised with 10,000 c-radiation attenuated WT, CSPSIINFEKL or
UIS4SIINFEKL sporozoites intravenously. 5 days later, mice were sacrificed, spleens harvested and splenocytes assessed for (D) CFSE dilution of CD8+ T cells, (E) CFSE
dilution of antigen-experienced Kb-SIINFEKL+ CD11ahi CD8+ T cells and stained ex vivo (F-H) for effector CD8+ T-cell surface markers. Shown are flow cytometry
plots of Kb-SIINFEKL co-staining with markers of effector phenotypes: (F) CD11ahi, (G) CD62Llo and (H) CD49dhi.
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splenocytes in order to augment the response and allow visualisa-
tion (Figs 2 and 3). Next, we wanted to explore whether we can
capture the endogenous Kb-SIINFEKL+ CD11ahi CD8+ T-cell
population, which is elicited by intravenous immunisation with c-
radiation attenuated sporozoites without OT-I cell transfer. We








Figure 3. Sporozoite surface antigen induces a higher CD8+ T-cell response than EEF vacuolar membrane antigen in the spleen and liver.
A Schematic overview of experimental design. C57BL/6 mice received 2 × 106 OT-I cells alone (n = 2–4) or were additionally immunised with 10,000 c-radiation
attenuated WT (n = 3–6), CSPSIINFEKL (n = 4) or UIS4SIINFEKL (n = 4) sporozoites intravenously. See Appendix Table S2 and S3 for the number of mice used for
pentamer staining and peptide restimulation. Spleens and livers were harvested either at day 14 or day 42.
B–G Proportions and numbers of (B-D) Kb-SIINFEKL+ CD8+ T cells were enumerated, or (E-G) IFN-c-secreting CD8+ T cells following restimulation ex vivo with SIINFEKL
peptide were quantified. Flow cytometry plots show representative percentages of CD8+ T cells co-stained with CD11a and (B) Kb-SIINFEKL or (E) IFN-c. The upper
panel of bar charts (C, F) show the percentage of co-stained CD8+ T cells and the lower panel (D, G) the absolute cell counts. Bar charts show mean values ( SEM)
from representative experiments (*P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA with Tukey’s multiple comparison test). See Appendix Table S4 for exact
P-values.
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Figure 4. Higher magnitude of endogenous SIINFEKL-specific CD8+ T-cell responses induced by a sporozoite antigen.
A Schematic overview of experimental design.
B–G C57BL/6 mice received 10,000 c-radiation attenuated WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites, either (B-D) intravenously (n = 6–8 mice per group) or (E-G)
intradermally (n = 4 mice per group). Additional control mice did not receive sporozoites (n = 6–8 intravenously, n = 4 intradermally). Spleens and livers were
harvested either at day 14 (n = 5 livers and n = 6 spleens for intravenous immunisation) or day 42 (n = 8 for intravenous immunisation), and IFN-c-secreting
lymphocytes following restimulation ex vivo with SIINFEKL peptide were quantified. Flow cytometry plots show representative percentages of CD8+ T cells co-
stained with IFN-c and CD11a (B, E). The upper panel of bar charts (C, F) show the percentage of CD11ahi IFN-c+ CD8+ T cells and the lower panel (D, G) the
absolute cell counts. Bar charts show mean values ( SEM) from representative experiments (*P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA with Tukey’s
multiple comparison test). See Appendix Table S4 for exact P-values.
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peptide followed by flow cytometry and were able to clearly identify
the endogenous population with a trend complementary to our
earlier results (Fig 4A–D). Immunisation with CSPSIINFEKL sporo-
zoites elicited a superior splenic and liver CD8+ T-cell response than
with UIS4SIINFEKL sporozoites. As expected, the proportion and
absolute cell numbers were considerably lower than with adoptive
transfer of OT-I cells, but this did not preclude the ability to detect
IFN-c-secreting CD8+ T cells and capture the differences between
the two groups.
Under normal conditions of transmission, sporozoites are
delivered into the host skin by mosquito bite. All preceding immuni-
sation experiments were performed with parasites injected intra-
venously. As a proxy for the natural route of infection, whilst
ensuring consistent quantities of parasites were inoculated, c-radia-
tion-attenuated CSPSIINFEKL and UIS4SIINFEKL sporozoites were
injected via the intradermal route into the ear pinnae. Under these
conditions, CSP still induced a greater number of IFN-c-secreting
SIINFEKL-specific CD8+ T cells following restimulation with SIIN-
FEKL compared with UIS4, with a comparable magnitude as after
intravenous injection (Fig 4E–G; Appendix Fig S3A). Thus, these
biologically and immunologically more appropriate data entirely
recapitulate the strong immunogenicity of a sporozoite surface anti-
gen compared with an EEF vacuolar membrane protein.
Increasing the amount of EEF vacuolar membrane antigen does
not impact its immunogenicity
CSP and UIS4 are critical proteins expressed by the sporozoite and
EEF, respectively, and both proteins are important for survival and
succession into the subsequent life stage and parasite form (Mueller
A
B C
Figure 5. Increasing antigen dose does not improve antigen-specific
CD8+ T-cell responses to an EEF vacuolar membrane protein.
A Schematic overview of experimental design. C57BL/6 mice (n = 4 per group)
received an intravenous dose of 8,000 c-radiation attenuated CSPSIINFEKL or
UIS4SIINFEKL sporozoites or 64,000 c-radiation attenuated UIS4SIINFEKL
sporozoites. Spleens and livers were harvested at day 12 and IFN-c-
secreting lymphocytes following restimulation ex vivo with SIINFEKL
peptide were quantified.
B Flow cytometry plots show representative CD8+ T cells co-stained with IFN-
c and CD11a.
C The upper panel of bar charts show the percentage of CD11ahi IFN-c+ CD8+
T cells and the lower panel the absolute cell counts. Bar charts show mean
values ( SEM) from representative experiments (***P < 0.001; one-way





Figure 6. Both sporozoite surface and EEF vacuolar membrane antigens
are susceptible to vaccine-induced CD8+ T cells for killing, resulting in
sterile protection.
A Schematic overview of experimental design. Mice received 2 × 106 OT-I
splenocytes, and 1 day later, they were either vaccinated with 1 × 108
ifu recombinant AdHu5 expressing whole ovalbumin (AdOVA) (n = 5 per
challenge group) or left untreated (n = 4 per challenge group).
B, C Flow cytometry (B) and scatter plots (C) represent CD8+ T cells derived
from peripheral blood co-stained with IFN-c and CD11a, following
ex vivo restimulation with SIINFEKL.
D Protective efficacy as measured by quantitative real-time PCR. Groups of
mice were vaccinated as described and challenged 19 days later with
10,000 WT (n = 7 non-vaccinated, n = 9 vaccinated), CSPSIINFEKL (n = 6
non-vaccinated, n = 4 vaccinated) or UIS4SIINFEKL sporozoites (n = 3 non-
vaccinated, n = 11 vaccinated). 42 h later livers were removed, and
parasite load was assessed by qPCR. Plots show the relative parasite load
of mice in each condition (**P < 0.01; Mann–Whitney U-test). See
Appendix Table S4 for exact P-values.
E Proportion of sterile protection after immunisation. Mice (vaccinated
group, n = 8; control group, n = 4) were vaccinated as described and
were challenged with 800 WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites.
Daily blood smears were taken from day 3 to 14 post-challenge to check
for parasitaemia.
Data information: Data for B-E are representative of two experiments
performed with scatter plots showing mean values ( SEM).
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et al, 2005; Coppi et al, 2011; Silvie et al, 2014). Previous studies
have shown that the magnitude of the CD8+ T-cell response to a
sporozoite surface antigen depended on the amount of parasites
used for immunisation (Hafalla et al, 2002). Hence, poor immuno-
genicity of an EEF vacuolar membrane protein could be a result of
the lower level of protein expression during parasite infection. It is
possible to enhance CD8+ T-cell responses by increasing the number
of parasites used for immunisation (Hafalla et al, 2002). Therefore,
we immunised groups of mice with 8,000 c-radiation-attenuated
CSPSIINFEKL, 8,000 UIS4SIINFEKL or 64,000 UIS4SIINFEKL sporozoites
and compared the magnitude of the elicited antigen-specific
responses. Strikingly, the CD8+ T-cell response following 8× sporo-
zoite immunisation dose with UIS4SIINFEKL did not increase
proportionally and was not significantly higher than immunisation
with a 1× dose (Fig 5A–C; Appendix Fig S3B). This result suggests
that, in the context of attenuated sporozoite immunisation, EEF
vacuolar membrane antigens are poorly immunogenic and increas-
ing antigen fails to substantially improve the magnitude of CD8+
T-cell responses.
Immunogenicity of parasite antigens does not predict effector
responses following vaccination
Our findings thus far showed that sporozoite surface proteins
appear more immunogenic than EEF vacuolar membrane proteins
and raised an intriguing and important question; does immuno-
genicity predict susceptibility to vaccine-induced effector responses?
To address this, we vaccinated mice, which had received OT-I cells,
with a recombinant adenovirus expressing full-length ovalbumin
(de Cassan et al, 2011) (Fig 6A). This vaccination protocol resulted
in frequencies of ~7.5% SIINFEKL-specific CD8+ T cells in peripheral
blood (Fig 6B and C; Appendix Fig S3C). Vaccinated mice were then
challenged with live CSPSIINFEKL or UIS4SIINFEKL sporozoites, and
protection was assessed 19 days after vaccination by two comple-
mentary assays; (i) determination of the reduction of parasite load
in the liver 42 h after sporozoite challenge (Fig 6D) and (ii) induc-
tion of sterile protection (Fig 6E). Vaccinated mice challenged with
CSPSIINFEKL or UIS4SIINFEKL sporozoites showed a dramatic reduction
in parasite load in the liver (Fig 6D) as compared to vaccinated mice
challenged with WT parasites. Strikingly, contrary to the differential
CD8+ T-cell responses induced by CSP and UIS4, there was no statis-
tical difference in the protection observed when vaccinated mice
were challenged with either CSPSIINFEKL or UIS4SIINFEKL sporozoites.
Consistent with these findings, both groups of vaccinated mice chal-
lenged with either CSPSIINFEKL or UIS4SIINFEKL sporozoites exhibited
sterile protection of comparable levels (Fig 6E; Table 1) determined
by microscopic analysis of blood smears post-challenge. These find-
ings indicate that spatial and temporal aspects of antigen expression
may affect protein immunogenicity in the context of parasitic infec-
tion but not necessarily the same target’s susceptibility for antigen-
specific CD8+ T-cell killing.
Discussion
The malaria pre-erythrocytic stages have been a prime target for the
development of a Pf vaccine for more than 35 years. Indeed, RTS,S/
AS01, the most advanced malaria sub-unit vaccine candidate to
date, is based on PfCSP, the major surface protein of sporozoites
(Cohen et al, 2010). Yet, final results of the Phase III trial showed
that RTS,S/AS01 offers only modest efficacy, which rapidly wanes
over time (Rts SCTP, 2015). Thus, there is an imperative need not
only to widen the pursuit for new sub-unit vaccine candidates, but
also to radically improve the antigen selection process. Antigens are
generally prioritised based on a range of criteria, including their
immunogenicity in the context of parasitic infection. We examined
this notion in an infection and vaccination model for Pb pre-erythro-
cytic stages. We evaluated whether antigen immunogenicity and
accessibility are decisive features of vaccine design.
The malaria pre-erythrocytic stages consist of two spatially dif-
ferent parasite forms: extracellular sporozoites and intracellular
EEFs. The transformation of sporozoites into EEFs involves regula-
tion at both transcriptional (Iwanaga et al, 2012) and translational
(Muller et al, 2011; Zhang et al, 2016) levels, resulting in divergent
spatial and temporal expression of many antigens that are distinct
for each parasite form (Tarun et al, 2008). Whilst our current under-
standing of immune responses to malaria pre-erythrocytic stages
has focussed on CSP, the lack of well-defined epitopes that are
expressed only by EEFs has restrained fundamental studies investi-
gating the contributions of EEF antigens in parasite-induced CD8+
T-cell responses and their value as target of vaccines.
In this study, we contrasted the development of CD8+ T-cell
responses induced by CSP and UIS4, two major proteins expressed
by sporozoites and EEFs, respectively. We generated transgenic Pb
parasites where SIINFEKL is expressed as part of either CSP or UIS4,
allowing the presentation of the epitope at the same space and time
as the respective protein. This approach is in contrast to a more
common strategy of expressing the whole, or a fragment of, ovalbu-
min inserted as a transgene into the Pb genome, and then tracking
the immune response elicited by an extraneous molecule (Lin et al,
2014; Montagna et al, 2014). Since CSP is expressed in both sporo-
zoites and EEFs, the processing and presentation of the SIINFEKL in
CSPSIINFEKL occurs as soon as sporozoites are inoculated and are
able to interact with CD11c+ dendritic cells, which cross-present
antigens via an endosome-to-cytosol pathway (Cockburn et al,
2011); CSP also has direct access to the hepatocyte’s cytosol for
Table 1. Prepatency of AdOVA immunised and challenged mice.a
Challenge WT WT CSPSIINFEKL CSPSIINFEKL UIS4SIINFEKL UIS4SIINFEKL
AdOVA Immunisation  +  +  +
Infected / Challenged 4 / 4 8 / 8 4 / 4 2 / 8 4 / 4 1 / 8
Prepatency (days) 3.75 4 3.35 (5)b 3.5 (5)b
aAll mice received 2 × 106 OT-1 cells 1 day prior to immunisation.
bBrackets are indicative of the small proportion of mice that became blood stage-positive at the day indicated, while all others remained negative until day 14.
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processing and presentation of the CSP-derived epitope (Cockburn
et al, 2011). Since UIS4 is expressed only in the PVM of EEFs,
processing and presentation of the epitope in UIS4SIINFEKL are
restricted to just hepatocytes, although a recent report has suggested
a role for monocyte-derived CD11c+ cells in acquiring parasites
during EEF stages (Kurup et al, 2019).
Our results establish that following sporozoite immunisation, a
sporozoite surface protein induces superior CD8+ T-cell responses—
as measured both by pentamer staining and by IFN-c secretion
following peptide stimulation—than an EEF vacuolar membrane
protein. Detailed kinetic and phenotypic analysis of the develop-
ment of antigen-specific CD8+ T cells to both CSP and UIS4 revealed
that the responses differ in magnitude, demonstrating the ability of
both antigens to elicit effector and effector memory responses.
There was no difference in our results whether sporozoites are
delivered using the commonly used intravenous immunisation or
the more physiological intradermal route. We also showed that
increasing the number of UIS4SIINFEKL parasites used for immunisa-
tion did not augment CD8+ T-cell responses, signifying that the poor
immunogenicity of an EEF vacuolar membrane protein is not due to
the level of UIS4 expression during parasite infection. Our findings
support the idea that EEF antigens have minimal contributions to
the magnitude of immune responses following whole sporozoite
immunisation, which corroborates with prior data showing that
hepatocytes are poor at priming T-cell responses (Thomson &
Knolle, 2010; Bertolino & Bowen, 2015).
In our initial experiments, mice received cells from transgenic
OT-I mice, which express SIINFEKL-specific TCRs on their CD8+ T
cells, prior to sporozoite immunisation. The results from these
experiments were compared with experimental set-ups, where mice
did not receive OT-I cells; the results of the latter solely quantified
the more physiological endogenous CD8+ T-cell response. As
expected, mice that received transgenic CD8+ T cells elicited higher
CD8+ T-cell responses—of one order of magnitude—as compared to
endogenous responses. Nonetheless, the trend of frequencies is
consistent in establishing that a sporozoite surface antigen induces a
higher CD8+ T-cell response than EEF vacuolar membrane antigen.
It is of fundamental interest to understand further the fine
specificities (i.e. proliferative capacity, phenotypic and functional
characteristics) and contributions of the transferred versus
endogenous CD8+ T cells in the resulting immune response. Further
investigations using congenic mice are warranted to address
these limitations.
CD8+ T cells recognise peptides directly processed and
presented by parasitised hepatocytes to exert their functions
(Bongfen et al, 2007; Chakravarty et al, 2007; Cockburn et al,
2011; Balam et al, 2012; Huang et al, 2015). Thus, we also evalu-
ated whether sporozoite or EEF-derived epitopes are accessible,
and therefore susceptible to vaccine-induced effector CD8+ T cells.
Regardless of their differing immunogenicities in the context of
parasitic infection, we demonstrated that both sporozoite and EEF
antigens are effectively targeted by antigen-specific effector CD8+
T cells, which were generated by vaccinating mice that received
OT-I cells with a recombinant adenovirus expressing the cognate
epitope. The transfer of OT-I ensured the induction of high levels
of vaccine-induced effector CD8+ T cells in a single vaccination,
with the ensuing frequencies comparable to those obtained by
prime-boost vaccinations with recombinant adeno- followed by
vaccinia viruses (Bruna-Romero et al, 2001; Gilbert et al, 2002;
Reyes-Sandoval et al, 2010; Reyes-Sandoval et al, 2011), or with
peptide-loaded dendritic cells followed by recombinant Listeria
(Doll et al, 2016). These prime-boost strategies have consistently
shown to induce high numbers of antigen-specific CD8+ T cells
(Bruna-Romero et al, 2001; Gilbert et al, 2002; Reyes-Sandoval
et al, 2010; Reyes-Sandoval et al, 2011; Doll et al, 2016) neces-
sary for protection (Schmidt et al, 2010). Previous work in mouse
models and CSP-based adenovirus vaccines showed the genera-
tion of endogenous responses that yielded only up to 40% sterile
immunity, despite two orders of magnitude in the reduction in
parasite load in the liver after challenge with viable sporozoites
(Rodrigues et al, 1997; Rodrigues et al, 1998). Importantly, using
the OT-I transfer model, our study shows that mice harbouring
similarly high levels of vaccine-induced, antigen-specific CD8+ T
cells were comparably protected when challenged with either
CSPSIINFEKL or UIS4SIINFEKL. These findings imply that both sporo-
zoite and EEF antigens comparably access the antigen presenta-
tion pathways in hepatocytes leading to recognition of defined
epitopes. Our study reiterates that high levels of vaccine-induced,
antigen-specific CD8+ T cells are needed to achieve protection in
mice, and likely in humans. Our work provides proof-of-concept
for vaccines targeting the complete malaria pre-erythrocytic
stages. The translational challenge will now be to design vaccine
formulations, which evoke and maintain high levels of antigen-
specific human CD8+ T cells either given as single dose or as part
of a prime-boost approach.
Our study is the first demonstration that poor natural immuno-
genicity, in this case of an EEF antigen, does not preclude anti-
gen-specific CD8+ T-cell killing. Our findings that antigen
immunogenicity in this context is an inadequate predictor of
vaccine efficacy have wide-ranging translational implications on
antigen prioritisation for the design and testing of next-generation
pre-erythrocytic Pf vaccines. Thus, the strategy to screen for T-cell
responses in naturally infected or sporozoite-immune human
volunteers to pre-clinically prioritise vaccine candidates requires
some form of reassessment. Conventional immunological assays,
aimed at identifying highly immunogenic antigens, may fail to
discover those candidates with the potential to induce superior
levels of protective immunity. For this proof-of-concept study, we
selected CSP and UIS4 as the best characterised representatives of
sporozoite and EEF vacuolar antigens. It will be interesting to
systematically compare global allelic diversity of sporozoite and
EEF antigens. The observation of allele-specific RTS,S/AS01
vaccine efficacy and low proportions of vaccine-matched CSP alle-
les in sub-Saharan Africa (Neafsey et al, 2015) underscores the
potential critical advantage of EEF antigens, which likely display
only moderate diversity across P. falciparum strains vis-a-vis
extended diversity of sporozoite surface antigens. It is noteworthy
that for other stages of malaria infection, conserved antigens that
give limited or no responses, e.g. PfRH5 (Douglas et al, 2011;
Osier et al, 2014) and sexual stage antigens (Kapulu et al, 2015),
are promising antibody targets for malaria vaccines under clinical
development. Together, our study establishes that EEF-expressed
antigens are prospective vaccine targets and thus effectively
increases the pool of existing pre-erythrocytic stage vaccine
targets for the malaria community to explore and translate to
clinical trials.
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A key direction for future research will be finding new assays to
easily distinguish and validate promising vaccine targets, namely
those antigens that can protect, via susceptibility to vaccine-induced
CD8+ T cells, rather than those that naturally induce strongly
immunogenic responses. In addition, our findings open new ques-
tions as to whether EEF-expressed antigens are optimal antigens for
the generation of endogenous liver-resident memory (TRM) CD8
+ T
cells. TRM cells were recently identified to persist in and continu-
ously perambulate the liver to evoke immune responses following
antigen challenge (Fernandez-Ruiz et al, 2016; Valencia-Hernandez
et al, 2020). Further work, utilising congenic mice, is warranted to
characterise in detail the intrahepatic cells induced by CSPSIINFEKL
and UIS4SIINFEKL parasites. There is current translational interest
in exploiting TRM cells for vaccine strategies against malaria
pre-erythrocytic stages. Current pre-clinical approaches are aimed at
initially activating T cells in the spleen by a priming vaccine, and
another delivery system is used to trap these cells in the liver to
form TRM cells. It is conceivable that EEF-expressed antigens could
already prime TRM cells, which can be boosted by novel vaccine
delivery systems.
Ultimately, the molecular mechanisms of presentation of EEF
antigens, those expressed in the PVM and within the parasite itself,
onto the surface of infected hepatocytes remains to be fully under-
stood. Determination of the processes involved in parasite antigen
presentation in the pre-erythrocytic stages of malaria may elucidate
links to protection and the identification of hitherto neglected anti-
gens that could drive the development of a highly efficacious
malaria vaccine.
Materials and Methods
Reagents and Tools table
Reagent Source Identifier
Antibodies
Anti-mouse CD3e-V500 (500A2) BD Biosciences Cat# 560771, RRID: AB_1937314
Anti-mouse CD8a-PerCP-Cy5.5 (53-6.7) Thermo Fisher Scientific Cat# 45-0081-82, RRID: AB_1107004
Anti-mouse CD11a-e450 (M17/4) Thermo Fisher Scientific Cat#48-0111-82, RRID: AB_11064445
Anti-mouse CD11a-FITC (M17/4) Thermo Fisher Scientific Cat#11-0111-82, RRID: AB_464931
Anti-mouse CD44-e450 (IM7) Thermo Fisher Scientific Cat# 48-0441-82, RRID: AB_1272246
Anti-mouse CD49d-PE (R1-2) Thermo Fisher Scientific Cat# 12-0492-82, RRID: AB_465697
Anti-mouse CD62L-PE-Cy7 (MEL-14) Thermo Fisher Scientific Cat# 25-0621-82, RRID: AB_469633
Anti-mouse IFN-c-APC (XMG1.2) Thermo Fisher Scientific Cat# 17-7311-82, RRID: AB_469504
Anti-mouse TNF-a-FITC (MP6-XT22) Thermo Fisher Scientific Cat# 11-7321-82, RRID: AB_465418
Anti-mouse IL-2-PE-Cy7 (JES6-5H4) Thermo Fisher Scientific Cat# 25-7021-82, RRID: AB_1235004
APC-labelled Pro5 MHC pentamer H-2-Kb-SIINFEKL ProImmune Customised
Anti-mouse CD45.2-Alexa647 (104) Biolegend Cat# 109818, RRID:AB_492870
Mouse anti-Plasmodium berghei CSP Potocnjak et al, 1980; PMID: 6991628 RRID:AB_2650479
Rabbit polyclonal anti-Plasmodium berghei UIS4 Muller et al, 2011: PMID: 21673790 N/A
Mouse anti-Plasmodium berghei HSP70 Tsuji et al, 1994: PMID: 8153120 RRID:AB_2650482
Alexa Fluor 488 goat anti-mouse Thermo Fisher Scientific Cat # A-11029 RRID:AB_2534088
Alexa Fluor 546 goat anti-rabbit Thermo Fisher Scientific Cat # A-11010 RRID:AB_2534077
Experimental Models: Cell Lines
Huh-7 Human hepatoma cells Nakabayashi, H., Taketa, K., Miyano, K.,
Yamane, T. & Sato, J. Growth of human
hepatoma cells lines with differentiated
functions in chemically defined medium.
Cancer Res. 42, 3858–3863 (1982).
Experimental Models: Organisms/Strains
C57BL/6J mice Charles River or LSHTM RRID:IMSR_JAX:000664
CD-1 mice LSHTM RRID:IMSR_CRL:22
NMRI mice Charles River RRID:IMSR_CRL:605
OT-I mice Charles River RRID:IMSR_CRL:642
Anopheles stephensi SK (Feldmann and Ponnudurai, 1989)
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Methods and Protocols
Ethics and animal experimentation
Animal procedures were performed in accordance with the
German “Tierschutzgesetz in der Fassung vom 18. Mai 2006
(BGBl. I S. 1207)” which implements the directive 2010/63/EU
from the European Union. Animal experiments at London School
of Hygiene and Tropical Medicine were conducted under licence
from the United Kingdom Home Office under the Animals (Scien-
tific Procedures) Act 1986. All animal experiments were carried
out under institutional care protocols. NMRI, CD-1, C57BL/6 and
OT-I laboratory mouse strains were bred in house at LSHTM or
purchased from Charles River Laboratories (Margate, UK or Sulz-
feld, Germany). Female mice were used for experiments at the
age of 6–8 weeks. Mice were placed into experimental cages of
the required sample size by animal staff and not investigators;
thus, an element of random group allocation occurred. Where
more animals were required for a particular cage, selected
animals were chosen at random for relocation. No blinding was
performed. Sample size was estimated based on our previous
experience and mouse availability. This project is in compliance
with the ARRIVE guidelines.
Generation of transgenic parasites
Transgenic P. berghei ANKA mutants CSPSIINFEKL and UIS4SIINFEKL
were developed using double homologous recombination. In the
CSPSIINFEKL mutant, the CSP gene is altered so the epitope SYIP-
SAEKI (residues 252-260) is replaced with the H-2b restricted Gallus
gallus ovalbumin epitope SIINFEKL. In the UIS4SIINFEKL mutant, the
SIINFEKL epitope is appended to the C-terminal end of the UIS4
protein. As such, B3D-CSPSIINFEKL plasmid was assembled by
successive cloning of three fragments, CSP-C, CSP-B and CSP-A,
obtained by PCR amplification from P. berghei ANKA genomic DNA
followed by restriction enzyme digestion. These fragments corre-
spond, respectively, to a 30 homology region downstream of CSP
(CSP-C, 0.7 kb), a fragment comprising the CSP ORF downstream of
the SYIPSAEKI epitope followed by the CSP 30 UTR (CSP-B, 0.8 kb)
and a fragment comprising a 50 promoter region followed by the
CSP-modified ORF where the SYIPSAEK coding sequence has been
replaced by a SIINFEKL coding sequence (CSP-A, 1.8 kb). The
resulting B3D-CSPSIINFEKL plasmid, containing the Toxoplasma
gondii dihydrofolate reductase/thymidylate synthase (TgDHFR/TS)
pyrimethamine resistance cassette flanked by CSP-A and CSP-B on
one side, and CSP-C on the other, was linearised with NotI and SacII
before transfection. Integration of the construct after double cross-
over homologous recombination results in replacement of the WT
CSP gene by a modified copy containing the SIINFEKL coding
sequence instead of the SYIPSAEKI coding sequence. The B3D-
UIS4SIINFEKL plasmid was assembled by successive cloning of three
fragments, UIS4-A, UIS4-B and UIS4-C, obtained by PCR amplifi-
cation from P. berghei ANKA genomic DNA followed by restriction
enzyme digestion. These fragments correspond, respectively, to a
fragment comprising a 50 upstream sequence followed by the UIS4
entire ORF fused in frame to the SIINFEKL coding sequence (UIS4-
A, 1.2 kb), to the UIS4 30 UTR sequence (UIS4-B, 0.6 kb) and to a 30
homology region downstream of UIS4 (UIS4-C, 0.9 kb). The result-
ing B3D-UIS4SIINFEKL plasmid, containing the TgDHFR/TS pyrimetha-
mine resistance cassette flanked by UIS4-A and UIS4-B on one side,
and UIS4-C on the other, was linearised with SacII and KpnI before
transfection. Integration of the construct after double crossover
homologous recombination results in replacement of the WT
UIS4 gene by a modified copy containing the SIINFEKL coding
sequence just upstream of a STOP codon. P. berghei CSPSIINFEKL and
UIS4SIINFEKL parasites were generated by transfection of P. berghei
ANKA with linearised B3D-CSPSIINFEKL and B3D-UIS4SIINFEKL plas-
mids, respectively. Purified schizonts of WT P. berghei ANKA
(clone c15cy1) were transfected with 5–10 lg of linearised plas-
mid by electroporation using the AMAXA NucleofectorTM device
(program U33), as described (Janse et al, 2006), and immediately
injected intravenously in the tail vein of a mouse. The day after
transfection, pyrimethamine (70 mg/l) was administrated in the
mouse drinking water, for selection of transgenic parasites. Trans-
genic clones were isolated after limiting dilution and injection
into mice. Correct integration of the constructs and purity of the
transgenic lines was verified by analytical PCR using primer
combinations specific for the unmodified CSP or UIS4 locus, and
for the 50 and 30 recombination events. All primers used in this
study are indicated in Table 2.
Plasmodium berghei ANKA immunisation
Plasmodium berghei WT (strain ANKA clone c15cy1 or clone 507)
parasites and CSPSIINFEKL and UIS4SIINFEKL (clone c15cy1) parasites
were maintained by continuous cycling between murine hosts
(NMRI or CD-1) and Anopheles stephensi mosquitoes. Infected
mosquitoes were kept in incubators (Panasonic and Mytron) at 80%
humidity and 20°C. Sporozoites were isolated from salivary glands
and c-irradiated at 1.2 × 104 cGy. Mice were immunised intra-
venously in the lateral tail vein or intradermally in the ear pinnae
with 10,000 sporozoites, unless otherwise stated, and challenged
with either 1,000 or 10,000 sporozoites injected intravenously.
Indirect fluorescent antibody staining (IFA) of sporozoites
Epoxy-covered 8-well glass slides were coated with 3% BSA-RPMI.
10,000 sporozoites were added per well in 3% BSA-RPMI and incu-
bated for 45 min during which the shed surface proteins are depos-
ited in the gliding motility process. Sporozoites and their trails were
stained with a mouse anti-CSP (Potocnjak et al, 1980) (1:300)
primary antibody and a rabbit polyclonal anti-PbUIS4 (Muller et al,
2011) (1:500) primary antibody and the respective fluorescently
labelled secondary antibodies (1:2,000). Nuclei were stained with
Hoechst 33342 (1:2,000) and slides mounted with “Fluoromount-G”
(Southern Biotech). Sporozoites and trails were analysed by fluores-
cent microscopy (Zeiss Axio Observer).
In vitro infection of hepatoma cells and fluorescent staining
In vitro EEF development was analysed in infected Huh7 hepa-
toma cells for 24 and 48 h. Triplicate Labtek (Permanox plastic—
Nunc) wells were infected with 10,000 transgenic CSPSIINFEKL or
UIS4SIINFEKL parasites and duplicate wells were infected with
10,000 WT parasites. Infected cells were analysed by fluorescence
microscopy using a mouse anti-PbHSP70 (Tsuji et al, 1994)
(1:300) and a rabbit polyclonal anti-PbUIS4 (Muller et al, 2011)
(1:500) primary antibody, the respective fluorescently labelled
secondary antibodies (1:2,000) and nuclear staining with Hoechst
33342 (1:2,000). Stainings were analysed by fluorescent micro-
scopy (Zeiss Axio Observer).
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Quantification of SIINFEKL-specific CD8+ T-cell responses
Spleens and livers were harvested from immunised or na€ıve mice
and perfused with PBS. Lymphocytes were derived from spleens
by passing through 40 or 70 lm cell strainers (Corning) and from
1× PBS-perfused livers by passing through 70 lm cell strainers
(Corning). Hepatocytes were removed from homogenised livers
using a modified 35% Percoll gradient (Goossens et al, 1990) (pre-
pared using ratio of 1.6 10× PBS (Gibco): 12.4 Percoll (GE Health-
care) : 24.1 incomplete RPMI (Gibco)). Red blood cells were lysed
with PharmLyse (BD), and lymphocytes were resuspended in
complete RPMI (cRPMI- RPMI + 10% FCS + 2% Penicillin-Strepto-
mycin + 1% L-glutamine (Gibco)). For cell counting, lymphocytes
were diluted 40× with Trypan Blue (Thermo Fisher Scientific) and
enumerated using a Neubauer “Improved” haemocytometer
(Biochrom). Alternatively, lymphocytes were counted using a
MACSQuant flow cytometer (Miltenyi Biotec), using propidium
iodide (PI) (1:1,250) (Sigma-Aldrich) or, in the case of intrahepatic
lymphocytes, using CD45.2-Alexa647 (1:400) (Biolegend) to distin-
guish between hepatocytes and lymphocytes, prior to PI adminis-
tration and counting. Peripheral blood was acquired by tail vein
puncture collected in Na+ heparin capillary tubes (Brand) and
assayed in 96-well flat bottom plates (Corning). For CD8+ T-cell
stimulations, 2–3 × 106 splenocytes or 1–2 × 105 liver cells were
incubated with SIINFEKL peptide (Peptides and Elephants,
Henningsdorf) at a final concentration of 10 lg/ml in the presence
of Brefeldin A (eBioScience). Cells were incubated at 37°C, 5%
CO2 for 5–6 h, before incubation at 4°C overnight. For staining of
cell surface markers and intracellular cytokines, cells were incu-
bated for 1 h at 4°C. Cells derived from the spleen or liver were
fixed with 4% paraformaldehyde, and cells from peripheral blood
were fixed with 1% paraformaldehyde between the extra- and
intracellular staining steps. Data were acquired by flow cytometry
using an LSRII or LSRFortessa (BD). Antibodies used for staining
were as follows; BD: CD3 (500A2) (1:300); eBioScience: CD8 (53-
6.7) (1:225), CD11a (M17/4) (1:300), CD49d (R1-2) (1:225),
CD62L (MEL-14) (1:250), CD44 (IM7) (1:250), IFN-c (XMG1.2)
(1:225), TNF (MP6-XT22) (1:250) and IL-2 (JES6-5H4) (1:250);
ProImmune: H-2-Kb-SIINFEKL pentamers (3 µl/test).
CFSE labelling of OT-I cells
Spleens from OT-I mice were lysed and cells washed twice in PBS
without serum. Splenocytes resuspended at a density of 5 × 106
cells/ml in PBS had 1:5,000 CFSE (Thermo Fisher Scientific) added
and were incubated in the dark at room temperature, with gentle
inversion for 4 min. The labelling reaction was quenched with
cRPMI and cells washed twice in cRPMI. Cells were recounted and
2 × 106 cells were injected per mouse.
Vaccination with OVA expressing recombinant adenovirus
To assess parasite liver load after vaccination with virus-expressed
OVA, groups of C57BL/6 mice were immunised with recombinant
human adenovirus serotype 5 (AdHu5) expressing full-length
chicken ovalbumin (de Cassan et al, 2011). Each mouse received
1 × 108 infective units (ifu) in a volume of 100 µl administered intra-
muscularly (50 µl into each thigh). One day prior, mice received
OT-I splenocytes intravenously (2 × 106 cells/mouse). 19 days after
vaccination, vaccinated and control mice were challenged with
10,000 WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites administered
Table 2. Primers used to generate plasmids and genotype parasites.
Oligonucleotide Sequence 50 30












Genotying of transgenic parasites TgDHFR forward CGCATTATATGAGTTCATTTTACACAATCC
OVA reverse CTAGTTTACAGTTTTTCAAAGTTGATTATAC
CSP WT forward TGTGAACTTTTCCTTATTTATTACGATTATG
CSP test forward AATATGAGCACGCTTTTACTTTGTCCAGG
CSP test reverse ACGAATCGAAATAAGTTACTATTCGTGCC
UIS4 test forward TGGTTCTTAATATTATTTTGGATACATGC
UIS4 test reverse CTCGTGTCCTTTGTAGTAAAAATAAACC
Restriction sites in the primer sequences are underlined.
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intravenously. 42 h after the challenge the livers were harvested and
homogenised in TRIzol (Thermo Fisher Scientific) for total RNA
isolation. Afterwards, cDNA was generated using the RETROScript
Kit (Ambion). Quantitative real-time PCR was performed using the
StepOnePlus Real-Time PCR System and Power SYBR Green PCR
Master Mix (Applied Biosystems). Relative liver parasite levels were
quantified using the DDCt method comparing levels of P. berghei
18S rRNA normalised to mouse GAPDH mRNA (Muller et al, 2011).
To assess sterile protection, AdHu5 OVA-vaccinated and control
mice received 2 × 106 OT-I splenocytes 1 day prior to vaccination.
14 days later, all mice were challenged with 800 WT, CSPSIINFEKL or
UIS4SIINFEKL sporozoites. Blood smears were taken from day 3 to 14
after challenge to determine the presence of blood stage parasites.
Statistics
Data were analysed using FlowJo version 9.5.3 (Tree Star Inc.,
Oregon, USA), Microsoft Excel and GraphPad Prism v9 (GraphPad
Software Inc., CA, USA). We used Mann–Whitney U-test for
analysing data that were not normally distributed and Welch’s t-test
or one-way ANOVA with Tukey’s multiple comparison test for
normally distributed data. Normal distribution was assessed using
Shapiro–Wilk test.
Data availability
This study includes no data deposited in external repositories.
Expanded View for this article is available online.
Acknowledgements
S.J.D is a Jenner Investigator, Lister Institute Research Prize Fellow and Well-
come Trust Senior Fellow (106917/Z/15/Z). K. Matuschewski was supported by
the Max Planck Society and grants from the European Commission (EviMalaR
Network of Excellence #34) and the Chica and Heinz Schaller Foundation. O.S.
was funded in part by the Laboratoire d’Excellence ParaFrap (ANR-11-LABX-
0024). J.C.R.H. was funded by grants from The Royal Society (University
Research Fellowship UF0762736/UF120026 and Project Grant RG130034) and
the National Centre for the Replacement, Refinement & Reduction of Animals
in Research (Project Grant NC/L000601/1). The funders had no role in study
design, data collection and analysis, decision to publish or preparation of the
manuscript. Parts of the illustrations used in the synopsis image were
obtained from Servier Medical Art, (https://smart.servier.com) licensed under a
Creative Commons Attribution 3.0 Unported License.
Author contributions
Experiment design: KMa, OS and JCRH; Transgenic parasites CSPSIINFEKL and
UIS4SIINFEKL : OS; Experiments and data analysis: KM€u, MPG, MR, OS and JCRH;
Adenovirus AdOVA: AR-S, AVSH and SJD; Manuscript writing: MPG and JCRH;
Manuscript comments and revision: All authors.
Conflict of interest
A.R.-S., A.V.S.H. and S.J.D. are named inventors on patent applications relating
to malaria vaccines, adenovirus vaccines and immunisation regimens.
References
Balam S, Romero JF, Bongfen SE, Guillaume P, Corradin G (2012) CSP–a
model for in vivo presentation of Plasmodium berghei sporozoite antigens
by hepatocytes. PLoS One 7: e51875
Bertolino P, Bowen DG, McCaughan GW, de St F, Groth B (2001) Antigen-
specific primary activation of CD8+ T cells within the liver. J Immunol 166:
5430 – 5438
Bertolino P, Bowen DG (2015) Malaria and the liver: immunological hide-and-
seek or subversion of immunity from within? Front Microbiol 6: 41
Bongfen SE, Torgler R, Romero JF, Renia L, Corradin G (2007) Plasmodium
berghei-infected primary hepatocytes process and present the
circumsporozoite protein to specific CD8+ T cells in vitro. J Immunol 178:
7054 – 7063
Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla JC, Tsuji M, Nussenzweig
RS (2001) Complete, long-lasting protection against malaria of mice
primed and boosted with two distinct viral vectors expressing the same
plasmodial antigen. Proc Natl Acad Sci USA 98: 11491 – 11496
de Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, Gupta P, Chauhan
VS, Chitnis CE, Gilbert SC, Hill AV et al (2011) The requirement for potent
adjuvants to enhance the immunogenicity and protective efficacy of
protein vaccines can be overcome by prior immunization with a
recombinant adenovirus. J Immunol 187: 2602 – 2616
Chakravarty S, Cockburn IA, Kuk S, Overstreet MG, Sacci JB, Zavala F (2007)
CD8+ T lymphocytes protective against malaria liver stages are primed in
skin-draining lymph nodes. Nat Med 13: 1035 – 1041
Cockburn IA, Tse SW, Radtke AJ, Srinivasan P, Chen YC, Sinnis P, Zavala F
(2011) Dendritic cells and hepatocytes use distinct pathways to process
protective antigen from Plasmodium in vivo. PLoS Pathog 7: e1001318
Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A (2010) From
the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum
Vaccines 6: 90 – 96
Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, Roggero MA, Corradin
G, Persson C, Tewari R, Sinnis P (2011) The malaria circumsporozoite
protein has two functional domains, each with distinct roles as




Antigen selection is critical for malaria vaccine discovery. To date,
sporozoite antigens are prioritised according to their immunogenicity,
accessibility and capacity to elicit inhibitory antibodies, and, to a
limited extent, cellular responses. Very little is known about the
vaccine potential of Plasmodium antigens expressed during liver infec-
tion.
Results
We have demonstrated in a mouse malaria model that despite having
poor immunogenicity, antigens expressed during liver infection are
excellent targets of vaccine-induced protection through cellular
immunity.
Impact
Our data provide a rationale for systematic evaluation of previously
unrecognised parasite-derived antigens for malaria vaccine discovery
and pre-clinical evaluation in formulations aimed at eliciting strong
cell-mediated immunity.
ª 2021 The Authors EMBO Molecular Medicine 13: e13390 | 2021 13 of 15
Katja M€uller et al EMBO Molecular Medicine
Doll KL, Pewe LL, Kurup SP, Harty JT (2016) Discriminating protective from
nonprotective Plasmodium-specific CD8+ T cell responses. J Immunol 196:
4253 – 4262
Doolan DL, Hoffman SL (2000) The complexity of protective immunity against
liver-stage malaria. J Immunol 165: 1453 – 1462
Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL,
Wyllie DH, Crosnier C, Miura K, Wright GJ et al (2011) The blood-stage
malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain
neutralizing antibody. Nat Commun 2: 601
Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, Long CA,
Seder RA (2018) Malaria vaccines: recent advances and new horizons. Cell
Host Microbe 24: 43 – 56
Feliu V, Vasseur V, Grover HS, Chu HH, Brown MJ, Wang J, Boyle JP, Robey EA,
Shastri N, Blanchard N (2013) Location of the CD8 T cell epitope within
the antigenic precursor determines immunogenicity and protection
against the Toxoplasma gondii parasite. PLoS Pathog 9: e1003449
Fernandez-Ruiz D, Ng WY, Holz LE, Ma JZ, Zaid A, Wong YC, Lau LS, Mollard
V, Cozijnsen A, Collins N et al (2016) Liver-resident memory CD8(+) T cells
form a front-line defense against malaria liver-stage infection. Immunity
45: 889 – 902
Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R, Hill AV
(2002) Enhanced CD8 T cell immunogenicity and protective efficacy in a
mouse malaria model using a recombinant adenoviral vaccine in
heterologous prime-boost immunisation regimes. Vaccine 20: 1039 – 1045
Goossens PL, Jouin H, Marchal G, Milon G (1990) Isolation and flow
cytometric analysis of the free lymphomyeloid cells present in murine
liver. J Immunol Methods 132: 137 – 144
Guebre-Xabier M, Schwenk R, Krzych U (1999) Memory phenotype CD8(+) T cells
persist in livers of mice protected against malaria by immunization with
attenuated Plasmodium berghei sporozoites. Eur J Immunol 29: 3978– 3986
Hafalla JC, Sano G, Carvalho LH, Morrot A, Zavala F (2002) Short-term
antigen presentation and single clonal burst limit the magnitude of the
CD8(+) T cell responses to malaria liver stages. Proc Natl Acad Sci USA 99:
11819 – 11824
Hafalla JC, Silvie O, Matuschewski K (2011) Cell biology and immunology of
malaria. Immunol Rev 240: 297 – 316
Hollingdale MR, Leland P, Leef JL, Leef MF, Beaudoin RL (1983) Serological
reactivity of in vitro cultured exoerythrocytic stages of Plasmodium berghei
in indirect immunofluorescent or immunoperoxidase antibody tests. Am J
Trop Med Hyg 32: 24 – 30
Huang J, Tsao T, Zhang M, Rai U, Tsuji M, Li X (2015) A sufficient role of MHC
class I molecules on hepatocytes in anti-plasmodial activity of CD8 (+) T
cells in vivo. Front Microbiol 6: 69
Iwanaga S, Kaneko I, Kato T, Yuda M (2012) Identification of an AP2-family
protein that is critical for malaria liver stage development. PLoS One 7:
e47557
Janse CJ, Franke-Fayard B, Mair GR, Ramesar J, Thiel C, Engelmann S,
Matuschewski K, van Gemert GJ, Sauerwein RW, Waters AP (2006) High
efficiency transfection of Plasmodium berghei facilitates novel selection
procedures. Mol Biochem Parasitol 145: 60 – 70
Kapulu MC, Da DF, Miura K, Li Y, Blagborough AM, Churcher TS, Nikolaeva D,
Williams AR, Goodman AL, Sangare I et al (2015) Comparative assessment
of transmission-blocking vaccine candidates against Plasmodium
falciparum. Sci Rep 5: 11193
Kurup SP, Anthony SM, Hancox LS, Vijay R, Pewe LL, Moioffer SJ, Sompallae R,
Janse CJ, Khan SM, Harty JT (2019) Monocyte-derived CD11c(+) cells
acquire Plasmodium from hepatocytes to prime CD8 T cell immunity to
liver-stage malaria. Cell Host Microbe 25: 565 – 577 e566
Lau LS, Fernandez-Ruiz D, Mollard V, Sturm A, Neller MA, Cozijnsen A,
Gregory JL, Davey GM, Jones CM, Lin YH et al (2014) CD8+ T cells from a
novel T cell receptor transgenic mouse induce liver-stage immunity that
can be boosted by blood-stage infection in rodent malaria. PLoS Pathog
10: e1004135
Lin JW, Shaw TN, Annoura T, Fougere A, Bouchier P, Chevalley-Maurel S,
Kroeze H, Franke-Fayard B, Janse CJ, Couper KN et al (2014) The
subcellular location of ovalbumin in Plasmodium berghei blood stages
influences the magnitude of T-cell responses. Infect Immun 82:
4654 – 4665
Mac-Daniel L, Buckwalter MR, Berthet M, Virk Y, Yui K, Albert ML, Gueirard P,
Menard R (2014) Local immune response to injection of Plasmodium
sporozoites into the skin. J Immunol 193: 1246 – 1257
Montagna GN, Beigier-Bompadre M, Becker M, Kroczek RA, Kaufmann SH,
Matuschewski K (2014) Antigen export during liver infection of the
malaria parasite augments protective immunity. MBio 5: e01321 – e1324
Mueller AK, Camargo N, Kaiser K, Andorfer C, Frevert U, Matuschewski K,
Kappe SH (2005) Plasmodium liver stage developmental arrest by
depletion of a protein at the parasite-host interface. Proc Natl Acad Sci
USA 102: 3022 – 3027
Muller K, Matuschewski K, Silvie O (2011) The Puf-family RNA-binding
protein Puf2 controls sporozoite conversion to liver stages in the malaria
parasite. PLoS One 6: e19860
Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, Lievens M,
Abdulla S, Adjei S, Agbenyega T et al (2015) Genetic diversity and
protective efficacy of the RTS, S/AS01 malaria vaccine. N Engl J Med 373:
2025 – 2037
Osier FH, Mackinnon MJ, Crosnier C, Fegan G, Kamuyu G, Wanaguru M,
Ogada E, McDade B, Rayner JC, Wright GJ et al (2014) New antigens for
a multicomponent blood-stage malaria vaccine. Sci Transl Med 6:
247ra102
Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V (1980) Monovalent
fragments (Fab) of monoclonal antibodies to a sporozoite surface
antigen (Pb44) protect mice against malarial infection. J Exp Med 151:
1504 – 1513
Rai D, Pham NL, Harty JT, Badovinac VP (2009) Tracking the total CD8 T
cell response to infection reveals substantial discordance in magnitude
and kinetics between inbred and outbred hosts. J Immunol 183:
7672 – 7681
Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, Colloca
S, Cortese R, Hill AV (2010) Prime-boost immunization with adenoviral
and modified vaccinia virus Ankara vectors enhances the durability and
polyfunctionality of protective malaria CD8+ T-cell responses. Infect
Immun 78: 145 – 153
Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, Rollier CS, Hill AV
(2011) CD8+ T effector memory cells protect against liver-stage malaria. J
Immunol 187: 1347 – 1357
Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M (1997) Single
immunizing dose of recombinant adenovirus efficiently induces CD8+ T
cell-mediated protective immunity against malaria. J Immunol 158:
1268 – 1274
Rodrigues EG, Zavala F, Nussenzweig RS, Wilson JM, Tsuji M (1998) Efficient
induction of protective anti-malaria immunity by recombinant adenovirus.
Vaccine 16: 1812 – 1817
Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala
F (1989) Cloned cytotoxic T cells recognize an epitope in the
circumsporozoite protein and protect against malaria. Nature 341:
323 – 326
14 of 15 EMBO Molecular Medicine 13: e13390 | 2021 ª 2021 The Authors
EMBO Molecular Medicine Katja M€uller et al
Rts SCTP (2015) Efficacy and safety of RTS, S/AS01 malaria vaccine with or
without a booster dose in infants and children in Africa: final results of a
phase 3, individually randomised, controlled trial. Lancet 386: 31 – 45
Sano G, Hafalla JC, Morrot A, Abe R, Lafaille JJ, Zavala F (2001) Swift
development of protective effector functions in naive CD8(+) T cells
against malaria liver stages. J Exp Med 194: 173 – 180
Schmidt NW, Butler NS, Badovinac VP, Harty JT (2010) Extreme CD8 T cell
requirements for anti-malarial liver-stage immunity following
immunization with radiation attenuated sporozoites. PLoS Pathog 6:
e1000998
Silvie O, Briquet S, Muller K, Manzoni G, Matuschewski K (2014) Post-
transcriptional silencing of UIS4 in Plasmodium berghei sporozoites is
important for host switch. Mol Microbiol 91: 1200 – 1213
Spielmann T, Fergusen DJ, Beck HP (2003) etramps, a new Plasmodium
falciparum gene family coding for developmentally regulated and highly
charged membrane proteins located at the parasite-host cell interface.
Mol Biol Cell 14: 1529 – 1544
Tarun AS, Peng X, Dumpit RF, Ogata Y, Silva-Rivera H, Camargo N, Daly TM,
Bergman LW, Kappe SH (2008) A combined transcriptome and proteome
survey of malaria parasite liver stages. Proc Natl Acad Sci USA 105:
305 – 310
Thomson AW, Knolle PA (2010) Antigen-presenting cell function in the
tolerogenic liver environment. Nat Rev Immunol 10: 753 – 766
Tsuji M, Mattei D, Nussenzweig RS, Eichinger D, Zavala F (1994)
Demonstration of heat-shock protein 70 in the sporozoite stage of malaria
parasites. Parasitol Res 80: 16 – 21
Valencia-Hernandez AM, Ng WY, Ghazanfari N, Ghilas S, de Menezes MN,
Holz LE, Huang C, English K, Naung M, Tan PS et al (2020) A natural
peptide antigen within the plasmodium ribosomal protein RPL6 confers
liver TRM cell-mediated immunity against malaria in mice. Cell Host
Microbe 27: 950 – 962 e957
Weiss WR, Mellouk S, Houghten RA, Sedegah M, Kumar S, Good MF,
Berzofsky JA, Miller LH, Hoffman SL (1990) Cytotoxic T cells recognize a
peptide from the circumsporozoite protein on malaria-infected
hepatocytes. J Exp Med 171: 763 – 773
WHO (2020) World Malaria Report 2020, Geneva, Switzerland: World Health
Organisation
Zhang M, Mishra S, Sakthivel R, Fontoura BM, Nussenzweig V (2016) UIS2: A
unique phosphatase required for the development of Plasmodium liver
stages. PLoS Pathog 12: e1005370
License: This is an open access article under the
terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in
any medium, provided the original work is properly
cited.
ª 2021 The Authors EMBO Molecular Medicine 13: e13390 | 2021 15 of 15
Katja M€uller et al EMBO Molecular Medicine
